Data on Promising Chemotherapy for Ovarian Cancer Being Presented Soon

Data on Promising Chemotherapy for Ovarian Cancer Being Presented Soon
DelMar Pharmaceutics and its collaborators at the University of Texas MD Anderson Cancer Center will soon present recent data regarding the activity of  the chemotherapy agent VAL-083 in ovarian cancer models, according to a recent company announcement. The results will be included in a poster, titled "Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin," and presented at the 11th Biennial Ovarian Cancer Research Symposium to be held Sept. 12–13 at the Rivkin Center for Ovarian Cancer in Seattle. VAL-083 is a first-in-class, small-molecule chemotherapeutic, with a novel molecular structure. It has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by the U.S. National Cancer Institute in a number of cancers, the company said on its website, and appears to show activity against a range of tumor types, including brain, lung, cervical, and ovarian tumors, as well as certain blood cancers, in clinical and preclinical tests. In ovarian cancers, particularly, VAL-083 has demonstrated in all tested cell lines both an ability to work in synergy with platinum-based chemotherapy, and to circumvent resistance to platinum-based chemotherapies. Women with ovarian cancer usually respond well initially to standard-of-care platinum-based chemotherapy, but most ovarian tumors become resistant to such therapies and progress within some 18 months. For these women, prognosis is poor and 
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *